Structure via PubChem · Public domain (PubChem)
Losmapimod
Sign in to saveAlso known as GS856553, GW856553
Losmapimod (GW856553X) is an investigational drug that reached stage III clinical trials for multiple medical conditions, but did not prove efficacy. It was most recently in development by Fulcrum Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Losmapimod selectively inhibits enzymes p38α/β mitogen-activated protein kinases (MAPKs), which are modulators of DUX4 expression and mediators of inflammation.
Chemical data
- Formula
- C22H26FN3O2
- Molecular weight
- 383.5 g/mol
- IUPAC name
- 6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide
- SMILES
- CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C
- InChIKey
- KKYABQBFGDZVNQ-UHFFFAOYSA-N
- XLogP
- 3.8
- Polar surface area
- 71.1 Ų
- H-bond donors
- 2
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- acute coronary syndrome, neuropathic pain, cardiovascular disease, focal segmental glomerulosclerosis
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 383.201
Show 3 more facts
- chemical formula
- C₂₂H₂₆FN₃O₂
- Commons category
- Losmapimod
- canonical SMILES
- CC1=C(C=C(C=C1C2=NC=C(C=C2)C(=O)NCC(C)(C)C)C(=O)NC3CC3)F
Sources (2)
via Wikidata · CC0